The company’s head office, located in Skopje, reported positive performance indicators, noting that its position within the Macedonian market has been consolidated. Financially, the firm reported that its sales in the domestic market increased by 24% over the corresponding period in the previous year. For the first six months of 2026, the company generated total revenue from its pharmaceutical segment amounting to 13.9 million euros.
The domestic market proved to be the primary contributor to this revenue, achieving sales of 4.8 million euros. This significant growth in the local market was highlighted as the key driver of the company’s results for the first half of the year. In addition to the revenue figures, the company disclosed specific financial provisions.
Following the reporting period, an amount of 9.1 million euros was reserved from the total sales revenue generated during the first six months of 2026. This report provides an overview of the company’s operational achievements and financial standing in the region. The documented growth in domestic sales underscores the company’s strengthened market presence and operational stability over the reporting period.
Topics: #six #months #increased
